| You are here: Home: BCU 9|2003: George W Sledge, MD: Select publications
Select publications
Publications discussed by Dr Sledge
Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003;Abstract 3646.
Miller KD et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (AvastinT) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76(Suppl 1);Abstract 36.
O'Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 200;21(4):588-92. Abstract
The role of VEGF expression in breast cancer
Dreisbach P et al. Vascular endothelial growth factor (VEGF) plasma levels and tumor expression in breast cancer: A comparison of random pre-operative VEGF plasma levels in malignant and benign breast disease. Proc ASCO 2002:Abstract 2986.
Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002;29(6 Suppl 16):10-4. Abstract
Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15- 8. Abstract
Gray R et al. The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). Proc ASCO 2003:Abstract 825.
Hoar FJ et al. Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma. Eur J Cancer 2003;39(12):1698-703. Abstract
Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29(3 Suppl 11):29-37. Abstract
Sledge GW Jr. Vascular endothelial growth factor in breast cancer: Biologic and therapeutic aspects. Semin Oncol 2002;29(3 Suppl 11):104-10. Abstract
|
